Overview

Praziquantel Bioequivalence Study

Status:
Completed
Trial end date:
2018-07-06
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to assess the bioequivalence (BE) of new 600 milligram (mg) Cisticid tablet (Test) versus 600 mg Biltricide tablets (Reference) at a dose of 1200 mg in healthy male participants. Praziquantel (PZQ) is the active ingredient for Cisticid and Biltricide tablets.
Phase:
Phase 1
Details
Lead Sponsor:
Merck KGaA
Merck KGaA, Darmstadt, Germany
Treatments:
Praziquantel